Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: pegylated liposomal doxorubicin
Sponsor: Chinese Academy of Medical Sciences
Collaborators: CSPC Ouyi Pharmaceutical Co., Ltd.